Document Detail


Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML.
MedLine Citation:
PMID:  19892307     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
BACKGROUND: The mammalian target of rapamycin (mTOR) has recently been identified as a potential target in acute myeloid leukemia (AML). METHODS: We treated 5 patients with chemotherapy-refractory AML with the mTOR-inhibitor rapamycin at 2mg per os daily for 14 days, with dose adjustment allowed to reach a target serum rapamycin concentration of 10-20 ng/mL. Four of five patients received additional hydroxyurea at constant dose during treatment with rapamycin. RESULTS: Two patients achieved a leukocyte response, in one of them, a prolonged response was seen. In the other patients, blast counts remained stable or increased during rapamycin therapy. We did not observe severe hematologic or non-hematologic side effects of rapamycin. CONCLUSION: Rapamycin at 2mg per day acts mildly cytoreductive in a subgroup of patients with refractory AML. Higher doses and drug combinations may be required to obtain long lasting anti-leukemic effects in these patients.
Authors:
Alexandra Boehm; Matthias Mayerhofer; Susanne Herndlhofer; Paul Knoebl; Christian Sillaber; Wolfgang R Sperr; Ulrich Jaeger; Peter Valent
Related Documents :
20597967 - Standard treatment of ph+ cml in 2010: how, when and where not to use what bcr/abl1 kin...
19446877 - Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia.
7967737 - Detection of mll gene rearrangements in adult acute lymphoblastic leukemia. a cancer an...
12850477 - Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (m...
9624557 - Comparative study between corpus cavernosum-electromyography findings and electron micr...
2340397 - Splenectomy for hypersplenism in chronic lymphocytic leukaemia and malignant non-hodgki...
Publication Detail:
Type:  Journal Article     Date:  2009-10-07
Journal Detail:
Title:  European journal of internal medicine     Volume:  20     ISSN:  1879-0828     ISO Abbreviation:  Eur. J. Intern. Med.     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-11-06     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9003220     Medline TA:  Eur J Intern Med     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  775-8     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Therapeutic implications of low lymphocyte count in non-ST segment elevation acute coronary syndrome...
Next Document:  Application of HRV-CD for estimation of life expectancy in various clinical disorders.